TVTX

Over the past six months, TVTX stock increased 98.63% over the last year but recently declined 11.26% in the past week and 18.51% in the past month as of early October 2026. In April 2026, the FDA approved FILSPARI for FSGS, making it the first and only approved treatment for the condition in the U.S. On August 4, 2026, the company reported strong Q2 2026 financial results, with U.S. net product sales reaching $161.4 million and FILSPARI sales surging 96% year-over-year, leading to a 14.2% stock gain. In September 2026, Travere received a Notice of Allowance extending FILSPARI's patent protection in FSGS into October 2037. Also in September 2026, a CEO transition was announced, with Bradley Campbell set to succeed Eric Dube in December 2026. Over the past 90 days, insiders sold approximately 1.05 million shares worth $66.3 million, including substantial sales by the CEO and an executive vice president under pre-arranged trading plans.